Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral methylprednisolone 625 mg vs 1250 mg for treatment of multiple sclerosis relapse
2012-001965-34Phase 4Completed
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylprednisolone in multiple sclerosis (MS) (2 arms), sponsored by Hospital Universitari Germans Trias i Pujol. Primary endpoints: Clinical non-inferiority in relapse improvement and Radiological efficacy. Started Aug 2012; status: completed.
02
Drugs
methylprednisolone
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-001965-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001965-34.